Inactive Instrument

Bonus BioGroup Ltd. TEL AVIV STOCK EXCHANGE

Equities

BONS

IL0004850116

Biotechnology & Medical Research

BoneUs Therapeutics Ltd. completed the acquisition of Oceana Advanced Industries Ltd. in a reverse merger transaction.

April 29, 2012 at 12:00 am EDT

BoneUs Therapeutics Ltd. signed a memorandum of understanding to acquire Oceana Advanced Industries Ltd. (TASE:OCEA) in a reverse merger transaction on July 17, 2011. BoneUs Therapeutics Ltd. completed the acquisition of Oceana Advanced Industries Ltd. (TASE:OCEA) in a reverse merger transaction on April 29, 2012.

Latest news about Bonus BioGroup Ltd.

Bonus BioGroup Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Bonus BioGroup Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Bonus BioGroup Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Bonus BioGroup Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Bonus BioGroup Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-30	CI
Bonus Biogroup Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-31	CI
Bonus BioGroup Ltd. announced that it expects to receive ILS 9 million in funding	17-04-10	CI
Bonus BioGroup Ltd. Auditor Raises 'Going Concern' Doubt	17-03-30	CI
Bonus BioGroup Ltd. announced that it has received ILS 8 million in funding	16-11-27	CI
Bonus BioGroup Ltd. announced that it expects to receive $1.46 million in funding	16-11-24	CI
Bonus BioGroup Ltd. announced that it expects to receive ILS 8 million in funding	16-10-04	CI
Bonus BioGroup Ltd. announced that it expects to receive ILS 4 million in funding	16-07-09	CI

Chart Bonus BioGroup Ltd.

Duration

Period

More charts

Company Profile

Bonus Biogroup Ltd, formerly Oceana Advanced Industries Ltd, is an Israel-based product-focused biotechnology company applying technology for supplying bone regeneration tissues. The Company is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. It is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Medical Devices

	1st Jan change	Capi.
MIMEDX GROUP, INC.	-25.77%	961M
NIBEC CO., LTD.	-19.12%	131M
KIM FOREST ENTERPRISE CO., LTD.	+10.84%	63.05M
COLLPLANT BIOTECHNOLOGIES LTD.	-15.49%	61.84M
NOVACYT	+13.60%	61.14M

Bio Medical Devices